A ma­jor­i­ty of FDA ad­vi­sors backed Replimune’s ad­vanced melanoma treat­ment, vot­ing in fa­vor of the prod­uct’s ef­fi­ca­cy and the da­ta pro­duced in its study, mark­ing a seis­mic vic­to­ry for the com­pa­ny that adds ad­di­tion­al pres­sure on the agency ahead of its fi­nal de­ci­sion...